Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 7, Number 1, February 2014, pages 17-22

An Evidence-Based Approach to the Management of Functional Dyspepsia Associated With Helicobacter pylori Infection

**Table 1.** Patients’ Data
	Age (years)	Total	P value
All P values were analyzed with Pearson chi-square test. H.P.: Helicobacter pylori; H2RB: H2-receptor antagonists; PPI: proton pump inhibit.
Case numbers (prevalence)	189 (16.5%)	186 (16.3%)	281 (24.6%)	254 (22.2%)	137 (12%)	74 (6.5%)	22 (1.9%)	1,143 (100%)
Gender
Male	84 (44.4%)	75 (40.3%)	105 (37.4%)	88 (34.6%)	53 (38.7%)	33 (44.6%)	17 (77.3%)	455 (39.8%)	0.04^b
Female	105 (55.6%)	111 (59.7%)	176 (62.6%)	166 (65.4%)	84 (61.3%)	41 (55.4%)	5 (22.7%)	688 (60..2%)
H.P.
Positive	9 ( 7.6%)	23 (20.4%)	44 (24.2%)	35 (19.4%)	19 (18.8%)	7 (15.2%)	2 (15.4%)	139 (18.5%)	0.03^b
Negative	109 (92.4%)	90 (79.6%)	138 (75.8%)	145 (80.6%)	82 (81.2%)	39 (84.8%)	11 (84.6%)	614 (81.5%)
Not done	71	73	99	74	36	28	9	390
Medications
PPI	92 (48.7%)	91 (49%)	136(48.4%)	127 (50.0%)	70 (51.1%)	40 (54.1%)	6 (27.3%)	562 (49.2%)	0.028^b
H2RB	51 (27.0%)	54 (29%)	60 (21.4%)	64 (25.2%)	39 (28.5%)	21 (28.4%)	13 (59.1%)	302 (26.4%)
Prokinetic agents	46 (24.3%)	41 (22%)	85 (30.2%)	63 (24.8%)	28 (20.4%)	13 (17.5%)	3 (73.6%)	279 (24.4%)
Clinic following
Improved	47 (70.1%)	58 (75.3%)	109 (78.4%)	108 (78.3%)	65 (74.7%)	37 (78.7%)	11 (68.8%)	435 (76.2%)	0.828^b
Worsen	20 (29.9%)	19 (24.7%)	30 (21.6%)	30 (21.7%)	22 (25.3%)	10 (21.3%)	5 (31.3%)	136 (23.8%)
Dropout	122	109	142	116	50	27	6	572

Table 1. Patients’ Data

Age (years)

Total

P value

20-29

30-39

40-49

50-59

60-69

70-79

> 80

All P values were analyzed with Pearson chi-square test. H.P.: Helicobacter pylori; H2RB: H2-receptor antagonists; PPI: proton pump inhibit.

Case numbers (prevalence)

189 (16.5%)

186 (16.3%)

281 (24.6%)

254 (22.2%)

137 (12%)

74 (6.5%)

22 (1.9%)

1,143 (100%)

Gender

Male

84 (44.4%)

75 (40.3%)

105 (37.4%)

88 (34.6%)

53 (38.7%)

33 (44.6%)

17 (77.3%)

455 (39.8%)

0.04^b

Female

105 (55.6%)

111 (59.7%)

176 (62.6%)

166 (65.4%)

84 (61.3%)

41 (55.4%)

5 (22.7%)

688 (60..2%)

H.P.

Positive

9 ( 7.6%)

23 (20.4%)

44 (24.2%)

35 (19.4%)

19 (18.8%)

7 (15.2%)

2 (15.4%)

139 (18.5%)

0.03^b

Negative

109 (92.4%)

90 (79.6%)

138 (75.8%)

145 (80.6%)

82 (81.2%)

39 (84.8%)

11 (84.6%)

614 (81.5%)

Not done

390

Medications

PPI

92 (48.7%)

91 (49%)

136(48.4%)

127 (50.0%)

70 (51.1%)

40 (54.1%)

6 (27.3%)

562 (49.2%)

0.028^b

H2RB

51 (27.0%)

54 (29%)

60 (21.4%)

64 (25.2%)

39 (28.5%)

21 (28.4%)

13 (59.1%)

302 (26.4%)

Prokinetic agents

46 (24.3%)

41 (22%)

85 (30.2%)

63 (24.8%)

28 (20.4%)

13 (17.5%)

3 (73.6%)

279 (24.4%)

Clinic following

Improved

47 (70.1%)

58 (75.3%)

109 (78.4%)

108 (78.3%)

65 (74.7%)

37 (78.7%)

11 (68.8%)

435 (76.2%)

0.828^b

Worsen

20 (29.9%)

19 (24.7%)

30 (21.6%)

30 (21.7%)

22 (25.3%)

10 (21.3%)

5 (31.3%)

136 (23.8%)

Dropout

122

109

142

116

572

**Table 2.** Patients’ Clinical Characteristics on Follow-Up
	Clinic following	Total	P value
P value of a: 0.203; b: 0.124; c: 0.116; d: 0.025. All P values were analyzed with Pearson chi-square test. H.P.: Helicobacter pylori; H2RB: H2-receptor antagonists; PPI: proton pump inhibit.
Gender
Male	176 (75.5%)	57 (24.5%)	233	0.828
Female	159 (76.6%)	79 (23.4%)	238
All except dropout
PPI	251 (77.2%)	74 (22.8%)	325	0.282
H2RB	125 (77.6%)	36 (22.4%)	161
Prokinetic agents	59 (69.4%)	26 (30.6%)	85
Total	435 (76.2%)	136 (23.8%)	571
Cases with H.P. infection
PPI^a	45 (84.9%)	8 (15.1%)	53	0.289
H2RB^b	18 (94.7%)	1 (5.3%)	19
Prokinetic agents^c	8 (100.0%)	0	8
Total^d	71 (88.8%)	9 (11.2%)	80
Cases without H.P. infection
PPI^a	149 (76.8%)	45 (23.2%)	194	0.789
H2RB^b	72 (80.0%)	18 (20.0%)	90
Prokinetic agents^c	34 (75.6%)	11 (24.4%)	45
Total^d	255 (77.5%)	74 (22.5%)	329

Table 2. Patients’ Clinical Characteristics on Follow-Up

Clinic following

Total

P value

Improved

Worsen

P value of a: 0.203; b: 0.124; c: 0.116; d: 0.025. All P values were analyzed with Pearson chi-square test. H.P.: Helicobacter pylori; H2RB: H2-receptor antagonists; PPI: proton pump inhibit.

Gender

Male

176 (75.5%)

57 (24.5%)

233

0.828

Female

159 (76.6%)

79 (23.4%)

238

All except dropout

PPI

251 (77.2%)

74 (22.8%)

325

0.282

H2RB

125 (77.6%)

36 (22.4%)

161

Prokinetic agents

59 (69.4%)

26 (30.6%)

Total

435 (76.2%)

136 (23.8%)

571

Cases with H.P. infection

PPI^a

45 (84.9%)

8 (15.1%)

0.289

H2RB^b

18 (94.7%)

1 (5.3%)

Prokinetic agents^c

8 (100.0%)

Total^d

71 (88.8%)

9 (11.2%)

Cases without H.P. infection

PPI^a

149 (76.8%)

45 (23.2%)

194

0.789

H2RB^b

72 (80.0%)

18 (20.0%)

Prokinetic agents^c

34 (75.6%)

11 (24.4%)

Total^d

255 (77.5%)

74 (22.5%)

329